Official Launch of VigiMobile and VigiUp Platforms to Strengthen the National Health Surveillance System

Rabat – The Moroccan Agency for Medicines and Health Products (AMMPS) officially launched VigiMobile and VigiUp on Wednesday in Rabat. These two digital platforms are designed to facilitate the reporting of adverse drug reactions and adverse events related to medicines and health products.

Organized as part of the international drug safety awareness campaign “Med Safety Week2026,” which runs from November 2 to 8 under the theme “Adverse Events: Don’t Ignore Them, Report Them,” this initiative aligns with the modernization of the national health system, in accordance with the directives of His Majesty King Mohammed VI, aimed at ensuring health and medicine safety.

The launch ceremony took place in the presence of, among others, the Secretary General of the Ministry of Health and Social Protection, Abdelkrim Mezine Belfkih, the Director General of the AMMPS (Moroccan Agency for Medicines and Health Products), Samir Ahid, institutional officials, representatives of healthcare facilities, and professionals in the sector.

Speaking at the event, the Minister of Health and Social Protection, Youns Bjijou, stated that with the launch of VigiMobile, for reporting adverse effects related to medications and vaccines, and VigiUp, for other health products, “we are providing professionals and citizens with simple and readily available tools.”

In a speech read on his behalf by Mr. Mezine Belfkih, Mr. Bjijou emphasized the importance of health vigilance mechanisms in supporting healthcare system reforms, as well as the need to promote a culture of reporting and strengthen coordination between national and local stakeholders.

The digital transformation of the national health system is not an end in itself, but it must facilitate user processes, improve the flow and processing of information, and strengthen the capacity of institutions to identify and respond to risks, he noted, adding that these two platforms are a concrete example of this.

For his part, Mr. Ahid highlighted the steps taken by the Agency to modernize monitoring systems, improve early risk detection, and facilitate the participation of healthcare professionals and citizens in the safety of medicines and health products. He emphasized the importance of strengthening the territorial health vigilance network through increased coordination among the various stakeholders in the health system.

For the AMMPS (Moroccan Agency for Medicines and Health Products), drug safety is not limited to marketing authorization but also relies on continuous monitoring, early risk detection, and a collective capacity to act to prevent any event likely to compromise patient health, he said.

This meeting also featured a panel discussion on the theme: “Notification, the cornerstone of vigilance: how to make every healthcare professional an active participant in patient safety?”, highlighting the role of healthcare professionals in identifying and reporting adverse events and their contribution to risk prevention.

As part of MedSafety Week 2026, the AMMPS is also implementing a national and regional awareness program, including initiatives for academics to benefit future healthcare professionals, as well as local activities conducted in coordination with the network of Regional Vigilance Centers.